FOLFOX Regimen for Clinically Aggressive Neuroendocrine Tumors: About one Case

#501

Introduction: The treatment for progressive metastatic well-differentiated pancreatic neuroendocrine tumors is based on adriamycin and streptozotocin chemotherapy, which achieves more than 60% tumor regression. However, severe adverse effects are common.

Aim(s): We report the case of a 55-year-old woman treated with a modified FOLFOX7 regimen.

Materials and methods: Clinical, biological and radiological data were collected in a patient with an aggressive advanced well-differentiated neuroendocrine pancreatic tumor treated by modified FOLFOX7.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Bengrine-Lefevre L, Marijon H, Afchain P, Tournigand C, De Gramont A,

Keywords: well-differentiated endocrine tumor, FOLFOX, thrombotic microangiopathy,